☆ 4.6 Article

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2 -Positive Tumours

PHARMACEUTICALS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Radiology, Nuclear Medicine & Medical Imaging

Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms

Francesca Borgna et al.

Summary: The study found that [Tb-161]Tb-DOTA-LM3 was more effective in inhibiting tumor cell viability compared to [Lu-177]Lu-DOTA-LM3 in both in vitro and in vivo experiments. In mice studies, [Tb-161]Tb-DOTA-LM3 significantly delayed tumor growth and prolonged survival compared to [Lu-177]Lu-DOTA-LM3. Terbium-161 also showed therapeutic advantages over lutetium-177 when combined with DOTATOC.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up

Anna Sundlov et al.

Summary: In patients with neuroendocrine tumors treated with Lu-177-DOTATATE, a significant decrease in IGF-1 levels was found, which may be attributed to radiation-induced damage. The decrease in IGF-1 levels was more pronounced in patients who received more treatment cycles and higher absorbed radiation doses.

NEUROENDOCRINOLOGY (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model

Jakob Albrecht et al.

Summary: Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin receptor (SSTR) analogs is a common approach in advanced neuroendocrine neoplasms. Recently, SSTR antagonists have shown promising results for imaging and therapy due to a higher number of binding sites than in commonly used agonists. Lu-177-DOTA-JR11 exhibited a higher tumor-to-kidney ratio, increased G2/M phase accumulation of cells, decreased tumor size, prolonged median survival, and stable tumor uptake over 2 treatment cycles compared to Lu-177-DOTATOC.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Chemistry, Medicinal

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [177Lu]Lu-OPS201 Compared to the Agonist [177Lu]Lu-DOTA-TATE

Rosalba Mansi et al.

Summary: Comparing the binding kinetics and cellular mechanisms of [Lu-177]Lu-OPS201 and [Lu-177]Lu-DOTA-TATE, the study found that [Lu-177]Lu-OPS201 recognized more receptor binding sites, with faster association and slower dissociation, explaining the improved therapeutic efficacy of [Lu-177]Lu-OPS201 compared to [Lu-177]Lu-DOTA-TATE.

PHARMACEUTICALS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Recombinant botulinum neurotoxin serotype A1 in vivo characterization

Cindy Perier et al.

Summary: The recombinant BoNT A1 (rBoNT/A1) exhibited similar properties to natural BoNT A1 (nBoNT/A1) in inhibiting motoneurons neurotransmitter release, resulting in long-lasting muscle strength suppression and impaired neurotransmitter release. The study suggests that rBoNT/A1 is a valuable tool for comparing with current and future neurotoxin products.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer

Marcus Ruscetti et al.

CELL (2020)

添加到收藏夹

Review Oncology

The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis

Jie Zhang et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model

Carleen Cullinane et al.

JOURNAL OF NUCLEAR MEDICINE (2020)

添加到收藏夹

Meeting Abstract Oncology

A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)

J. Capdevila et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Radiopharmaceutical therapy in cancer: clinical advances and challenges

George Sgouros et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

添加到收藏夹

Review Oncology

Senescent Cells in Cancer Therapy: Friends or Foes?

Boshi Wang et al.

TRENDS IN CANCER (2020)

添加到收藏夹

Article Oncology

Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan

Diane Reidy-Lagunes et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors

Satya Das et al.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect

Guillaume P. Nicolas et al.

JOURNAL OF NUCLEAR MEDICINE (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models

Simone U. Dalm et al.

JOURNAL OF NUCLEAR MEDICINE (2016)

添加到收藏夹

Review Urology & Nephrology

Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease

Rikke Nielsen et al.

KIDNEY INTERNATIONAL (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Analysis of 177Lu-DOTA-Octreotate Therapy-Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors

Delphine Denoyer et al.

JOURNAL OF NUCLEAR MEDICINE (2015)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study

Damian Wild et al.

JOURNAL OF NUCLEAR MEDICINE (2014)

添加到收藏夹

Article Multidisciplinary Sciences

DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy

Franziska Graf et al.

PLOS ONE (2014)

添加到收藏夹

Article Pharmacology & Pharmacy

Chloroquine causes similar electroretinogram modifications, neuronal phospholipidosis and marked impairment of synaptic vesicle transport in Albino and Pigmented Rats

Stephane Lezmi et al.

TOXICOLOGY (2013)

添加到收藏夹

Article Endocrinology & Metabolism

Agonist-Biased Signaling at the sst2A Receptor: The Multi-Somatostatin Analogs KE108 and SOM230 Activate and Antagonize Distinct Signaling Pathways

Renzo Cescato et al.

MOLECULAR ENDOCRINOLOGY (2010)

添加到收藏夹

Review Biochemistry & Molecular Biology

H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy

Monika Podhorecka et al.

JOURNAL OF NUCLEIC ACIDS (2010)

添加到收藏夹

Article Multidisciplinary Sciences

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Wen Xue et al.

NATURE (2007)

添加到收藏夹

Article Multidisciplinary Sciences

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

Mihaela Ginj et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.